MX2007005611A - Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados. - Google Patents

Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.

Info

Publication number
MX2007005611A
MX2007005611A MX2007005611A MX2007005611A MX2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A MX 2007005611 A MX2007005611 A MX 2007005611A
Authority
MX
Mexico
Prior art keywords
sub
imidazo
pyridine compounds
compositions
methods related
Prior art date
Application number
MX2007005611A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Guglietta
Albert Palomer
Jose Luis Falco
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MX2007005611A publication Critical patent/MX2007005611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2007005611A 2004-11-11 2005-11-04 Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados. MX2007005611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105698 2004-11-11
PCT/EP2005/055753 WO2006051063A1 (en) 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto

Publications (1)

Publication Number Publication Date
MX2007005611A true MX2007005611A (es) 2007-07-11

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005611A MX2007005611A (es) 2004-11-11 2005-11-04 Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.

Country Status (24)

Country Link
US (1) US20080200473A1 (https=)
EP (1) EP1814880B1 (https=)
JP (1) JP2008519805A (https=)
KR (1) KR20070084026A (https=)
CN (1) CN101065377B (https=)
AR (1) AR051626A1 (https=)
AT (1) ATE421962T1 (https=)
AU (1) AU2005303811A1 (https=)
BR (1) BRPI0517796A (https=)
CA (1) CA2585315A1 (https=)
DE (1) DE602005012598D1 (https=)
DK (1) DK1814880T3 (https=)
ES (1) ES2321858T3 (https=)
IL (1) IL182963A0 (https=)
MX (1) MX2007005611A (https=)
NO (1) NO20072831L (https=)
PA (1) PA8652101A1 (https=)
PE (1) PE20060967A1 (https=)
PL (1) PL1814880T3 (https=)
PT (1) PT1814880E (https=)
RU (1) RU2007121864A (https=)
TW (1) TWI357412B (https=)
UY (1) UY29204A1 (https=)
WO (1) WO2006051063A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
AU2007267183B2 (en) * 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
CN101528226B (zh) * 2006-08-24 2012-01-11 澳大利亚核科学技术组织 靶向外周苯二氮卓受体的氟化配体
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
CA2724842A1 (en) * 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
US10478438B2 (en) 2008-10-16 2019-11-19 David Reed Helton Treatment of organophosphate exposure with ocinaplon
US20120010188A1 (en) * 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
EP2496578A4 (en) 2009-11-05 2013-08-21 Univ Notre Dame Du Lac IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230121497A1 (en) * 2020-01-29 2023-04-20 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3167275A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
CN118515663A (zh) * 2023-04-24 2024-08-20 上海赛默罗生物科技有限公司 咪唑并吡啶或咪唑并吡嗪类化合物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ATE62687T1 (de) * 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
US20040204443A1 (en) * 2003-01-27 2004-10-14 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Also Published As

Publication number Publication date
EP1814880A1 (en) 2007-08-08
AR051626A1 (es) 2007-01-24
CN101065377B (zh) 2011-07-27
PA8652101A1 (es) 2006-10-13
UY29204A1 (es) 2006-01-31
PE20060967A1 (es) 2006-09-20
CA2585315A1 (en) 2006-05-18
EP1814880B1 (en) 2009-01-28
DE602005012598D1 (de) 2009-03-19
TW200624432A (en) 2006-07-16
PL1814880T3 (pl) 2009-07-31
ATE421962T1 (de) 2009-02-15
IL182963A0 (en) 2007-08-19
WO2006051063A1 (en) 2006-05-18
RU2007121864A (ru) 2008-12-20
BRPI0517796A (pt) 2008-10-28
PT1814880E (pt) 2009-04-23
TWI357412B (en) 2012-02-01
AU2005303811A1 (en) 2006-05-18
CN101065377A (zh) 2007-10-31
ES2321858T3 (es) 2009-06-12
US20080200473A1 (en) 2008-08-21
KR20070084026A (ko) 2007-08-24
JP2008519805A (ja) 2008-06-12
DK1814880T3 (da) 2009-05-18
NO20072831L (no) 2007-08-01

Similar Documents

Publication Publication Date Title
MX2007005611A (es) Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
WO2007138472A3 (en) Triazolopyridazine derivatives
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
MEP23808A (en) Pyridine[3,4-b]pyrazinones
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
WO2006011050A3 (en) Pyridine derivatives
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
WO2009023844A3 (en) 3' substituted compounds having 5-ht6 receptor affinity
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
UA99447C2 (ru) Способ получения силденафила
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
WO2007147771A3 (en) Tetralin and indane derivatives and uses thereof
WO2008147812A3 (en) 4' substituted compounds having 5-ht6 receptor affinity
WO2008101247A3 (en) 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
WO2010011546A3 (en) Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity
AU2004216182A1 (en) Selective non-steroidal glucocorticoid receptor modulators
WO2005007087A3 (en) Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
WO2004093805A3 (en) Selective spirocyclic glucocorticoid receptor modulators
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2007017728A3 (en) Novel heterocyclic compounds
TW200514785A (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
TW200510422A (en) N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides and compositions and methods related thereto

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general